CentrumPR.pl

 Warsaw/Monaco, September 5, 2025

Carlson Investments SE is pleased to present the progress of its portfolio company Bioaccure , which has developed a compact, next-generation molecular diagnostics platform that enables real-time PCR testing at the point of sampling.

Unlike traditional PCR systems that require complex laboratory facilities and refrigerated sample transport, Bioaccure's patented PCR.smart analyzer integrates sample preparation, DNA isolation, amplification, detection, and result interpretation into a single device. This delivers laboratory-quality results in less than 90 minutes, making advanced diagnostics accessible in the field and in challenging environments.

The solution is used in plant and animal health protection, food safety, water quality testing, and veterinary diagnostics. Bioaccure provides farmers, food producers, distributors, veterinarians, and inspectors with the ability to quickly and precisely detect pathogens at a significantly lower cost. Available test kits already cover Salmonella spp., Campylobacter spp., Listeria monocytogenes, E. coli , and Fusarium species , and the portfolio is constantly expanding with new solutions tailored to market needs.

Key features of Bioaccure:

• A mobile device that allows PCR tests to be performed where the sample is taken,

• The complete process – from DNA isolation to results interpretation – in less than 90 minutes,

• Support for qPCR, PCR and LAMP tests,

• No need to store samples in cold storage or transport them,

• Ability to detect bacteria, viruses, fungi, parasites and genetic mutations,

• Simple, intuitive operation – even for people without specialist knowledge.

About Bioaccure Bioaccure is an innovative diagnostics company specializing in real-time PCR systems for field and industrial applications. Its patented PCR.smart technology combines portability, accuracy, and speed to deliver laboratory-quality results in agriculture, veterinary medicine, and food safety.

About Carlson Investments SE: Carlson Investments SE, listed on the Warsaw NewConnect market and the German Open Markets (Frankfurt, Munich, Stuttgart, Gettex), invests in innovative, early-stage technology companies, including those in the healthtech, AI, fintech, and deeptech sectors. Carlson pursues an active investment approach and provides its portfolio companies with access to a global network of strategic partners.

Risk Disclaimer This information:

• does not constitute an investment recommendation or an offer to buy or sell financial instruments,

• involves risk, including the possibility of loss of capital,

• does not guarantee future results,

• and historical results are not a guarantee of future results.

Our shares are listed on:

Warsaw Stock Exchange (PLN): CAI, PLHOTB000011 Frankfurt Stock Exchange (EUR): 2HB (FRA), PLHOTB000011 Munich Stock Exchange (EUR): 2HB (MUN), PLHOTB000011 Stuttgart Stock Exchange (EUR): 2HB (STU), PLHOTB000011 GETTEX Exchange (EUR): 2HB (GET), PLHOTB000011 WKN: A0RNWQ

Media contact: Carlson Investments SE Management Office ir@carlsonvc.com www.carlsonvc.com